clopidogrel / Generic mfg. - LARVOL DELTA

UNILATERAL RENAL ARTERY THROMBOSIS PRESENTING WITH ACUTE KIDNEY INJURY: DIAGNOSTIC AND THERAPEUTIC CHALLENGES (ISN-WCN 2026) - "Continuous intravenous heparin infusion (10,000 units/24 hours) was started for anticoagulation, followed by percutaneous thrombectomy...Maintenance therapy with warfarin and clopidogrel was given to prevent recurrence...Early vascular imaging is crucial in sudden-onset renal failure with nonspecific laboratory findings2. Long-term antithrombotic therapy may prevent recurrence in idiopathic or hypercoagulable conditions2,3.Conclusion Renal artery thrombosis is an uncommon but critical cause of acute kidney injury that demands prompt recognition and swift intervention"

Acute Kidney Injury • Atherosclerosis • Atrial Fibrillation • Cardiovascular • Diabetes • Diabetic Nephropathy • Hypertension • Infectious Disease • Metabolic Disorders • Nephrology • Novel Coronavirus Disease • Renal Disease • Thrombosis

Hematuria-related readmission after transurethral resection of bladder tumor in patients receiving antiplatelet therapy. (PubMed, Urologia) - "Perioperative ASA monotherapy appears safe, while clopidogrel use may increase the risk of hematuria-related readmission and warrants closer monitoring."

Journal • Bladder Cancer • Cardiovascular • Genito-urinary Cancer • Oncology • Solid Tumor

Economic Evaluation of Pre-emptive Pharmacogenetic Panel Testing versus No Genetic Testing in a Multi-ethnic Asian Population. (PubMed, Pharmacoeconomics) - "Pre-emptive PGx panel testing is economically viable when panel design, variant prevalence, drug costs, and local prescribing patterns are carefully considered. As more data become available, the model can be tailored to evaluate additional drug-gene pairs and their downstream consequences."

Biomarker • HEOR • Journal • CYP2C19 • DPYD • HLA-B

The Anesthetic Management of a Patient With Advanced Heart Failure Undergoing Non-cardiac Surgery. (PubMed, Cureus) - "We present the case of a 73-year-old male with severe HF (LVEF 18%), a permanent pacemaker, severe anemia, and ongoing clopidogrel therapy who required urgent fixation of an open distal humerus fracture...An ultrasound-guided supraclavicular brachial plexus block was performed using 20 mL of 0.5% ropivacaine...Ultrasound guidance allows for precise needle placement and may reduce complications, even in patients receiving antiplatelet therapy, when the benefits outweigh the risks. An ultrasound-guided supraclavicular block proved to be a safe and effective anesthetic strategy in a patient with severe HF undergoing emergency orthopedic surgery."

Journal • Anesthesia • Cardiovascular • CNS Disorders • Congestive Heart Failure • Depression • Heart Failure • Hematological Disorders • Musculoskeletal Diseases • Orthopedics • Psychiatry

CLOPIDOGREL MODULATES NEURON-GLIA INTERACTIONS AND COGNITIVE FUNCTION IN ALZHEIMER'S DISEASE MODELS (ADPD 2026) - "These findings support a beneficial role for clopidogrel in AD possible through preventing synaptic degeneration, as evidenced by both real-world data and experimental models. This study highlights clopidogrel as a promising candidate for drug repurposing in AD prevention and treatment."

Alzheimer's Disease • CNS Disorders • Dementia • Aβ42

Aspirin vs. Clopidogrel Monotherapy Beyond 1 Month After Percutaneous Coronary Intervention in Patients With Diabetes　- Prespecified Subgroup Analysis of the STOPDAPT-3 Trial. (PubMed, Circ J) - "From 30 days to 1 year after PCI, cardiovascular outcomes were similar between aspirin and clopidogrel regardless of diabetes. A nominal bleeding interaction was observed; given the exploratory and underpowered subgroup analyses, this finding should be interpreted cautiously."

Journal • Monotherapy • Cardiovascular • Diabetes • Hematological Disorders • Metabolic Disorders • Myocardial Infarction • Thrombosis

A multidimensional study of antiplatelet therapy and CYP2C19 genetic testing in patients with ischemic stroke and transient ischemic attack. (PubMed, Clin Neurol Neurosurg) - "The adherence to guidelines regarding antiplatelet therapy and CYP2C19 genetic testing among patients with ischemic stroke and transient ischemic attack remains suboptimal, and the clinical utility of genetic testing is yet to be fully realized. Pharmacists should deliver comprehensive and precise pharmaceutical services from multiple perspectives to promote the rationalization and individualization of antiplatelet therapy."

Journal • Cardiovascular • Gene Therapies • Ischemic stroke • CYP2C19

Clopidogrel Versus Aspirin Monotherapy Beyond 1 Year After PCI: The Final 5-Year Results of the STOPDAPT-2 ACS and STOPDAPT-2 Total Cohort. (PubMed, Circ Cardiovasc Interv) - P4 | "The patients after percutaneous coronary intervention with cobalt-chromium everolimus-eluting stents were randomized into 1-month dual antiplatelet therapy followed by clopidogrel monotherapy (clopidogrel group) or 12-month dual antiplatelet therapy followed by aspirin monotherapy (aspirin group). Clopidogrel monotherapy was superior to aspirin monotherapy for cardiovascular outcomes beyond 1 year after percutaneous coronary intervention, without increased bleeding risk. URL: https://www.clinicaltrials.gov; Unique identifier: NCT02619760 and NCT03462498."

Clinical • Journal • Monotherapy • Acute Coronary Syndrome • Cardiovascular • Hematological Disorders • Myocardial Infarction • Thrombosis

Response to: Comment on 'comparative effectiveness of clopidogrel vs. potent P2Y12 inhibitors in CYP2C19 normal metabolizers following percutaneous coronary intervention: A real-world cohort study'. (PubMed, Br J Clin Pharmacol) - No abstract available

HEOR • Journal • Real-world evidence • CYP2C19

Contemporary Trends in High-Potency P2Y12 Receptor Inhibitor Use Among Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention. (PubMed, J Am Heart Assoc) - "Among patients with AMI undergoing PCI, the use of high-potency agents continues to rise. Prasugrel use increased notably after 2019, following the ISAR-REACT 5 (Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome) trial and the European guideline updates. These findings reflect an evolving prescribing landscape of P2Y12 receptor inhibitors in contemporary practice."

Journal • Acute Coronary Syndrome • Cardiovascular • Chronic Kidney Disease • Genetic Disorders • Myocardial Infarction • Nephrology • Obesity • Renal Disease

Small Pontine Infarction Secondary to Posterior Inferior Cerebellar Artery (PICA) Atherosclerosis: The Diagnostic Value of 3 Tesla MRI. (PubMed, Cureus) - "The patient was managed with dual antiplatelet therapy (DAPT) (clopidogrel 75 mg and aspirin 100 mg), high-intensity statin (rosuvastatin 20 mg), and stringent blood pressure control. The 3 Tesla MRI is a pivotal tool for detecting small-core infarcts and evaluating detailed atherosclerotic changes in the posterior circulation. Integrating clinical vigilance with advanced imaging facilitates accurate diagnosis and optimizes medical management to prevent recurrent stroke."

Journal • Atherosclerosis • Cardiovascular • Dyslipidemia • Hypertension • Ischemic stroke • Metabolic Disorders • Otorhinolaryngology • Pain • Vertigo

Signal detection of drug-induced esophageal ulcer across 20 years of real-world study: Focus on 49 high-risk medicines. (PubMed, J Int Med Res) - "Aspirin, alendronic acid, and doxycycline were most frequently reported; doxycycline, clindamycin, and alendronic acid generated the strongest safety signals. Notably, tacrolimus, sunitinib, meclofenamic acid, clopidogrel, and erlotinib were associated with esophageal ulcers but remain unlabeled for this risk.ConclusionsThis study provides a comprehensive drug-induced esophageal ulcer risk profile, highlighting high-risk drugs beyond commonly recognized agents. These findings can inform safer prescribing practices, patient counseling, and targeted pharmacovigilance."

Journal • Real-world evidence • Musculoskeletal Diseases • Oncology

Variable Clopidogrel Response in Pediatric Patients: A Call for Monitoring (SCCM 2026) - "Clopidogrel dosing and response varied across pediatric age groups. Platelet function testing often revealed suboptimal response, prompting dose changes in over half of tested patients. Bleeding was linked with hyper-responsiveness (VN 180), supporting the need for monitoring to guide safer and individualized dosing."

Clinical • Cardiovascular • Hematological Disorders • Pediatrics • Thrombosis

Outcomes of Clopidogrel vs Potent P2Y12 Inhibitors in Patients With ACS and AF on OAC (SCCM 2026) - "However, limited data exist on the safety and efficacy of potent P2Y12 inhibitors, such as ticagrelor and prasugrel, when combined with OAC in this population. This study contributes to the small but growing body of literature evaluating combinations of OAC with clopidogrel versus potent P2Y12 inhibitors. It offers some insight into real-world clinical outcomes. Although no statistically significant safety or efficacy differences were observed, the numerically lower rate of MACE in the potent P2Y12 group may reflect enhanced antiplatelet efficacy, warranting further investigation."

Clinical • Acute Coronary Syndrome • Atrial Fibrillation • Cardiovascular • Hematological Disorders • Thrombosis

Use of Cangrelor and Platelet Reactivity Unit Monitoring in Patients With Acute Ischemic Stroke (SCCM 2026) - "Cangrelor may be a safe alternative antiplatelet agent in patients who could not receive oral P2Y12 inhibitors in acute ischemic stroke. PRU assay monitoring could be considered."

Clinical • Cardiovascular • Ischemic stroke

Impact of Proton Pump Inhibitor Use on CYP2C19 Phenoconversion as Evidenced by Major Adverse Cardiovascular Events Recurrence in Clopidogrel-Treated Patients: A Systematic Review and Meta-Analysis (THSNA 2026) - "Future studies are warranted to determine phenotype-stratified interaction outcomes and help prevent antiplatelet clinical resistance. No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the author."

Adverse events • Retrospective data • Review • Cardiovascular • CYP2C19

Standard vs Alternative DAPT Strategies for Intracranial Aneurysms Treated With Flow-Diverting Stent (SCCM 2026) - "In the standard group the most common DAPT regimen was aspirin plus clopidogrel 75 mg daily (100%), while the most common regimen in the alterative group was clopidogrel 75 mg every other day (64.7%)... Using standard or alternative DAPT regimens (directed by VerifyNow tests) in patients with the Pipeline TM Flex Embolization Device with Shield Technology TM demonstrated similar safety and efficacy outcomes. Further research on DAPT dosing strategies with the Pipeline TM Flex device, and other new generation flow diverting stents, is needed to determine their effect on patient outcomes."

Cardiovascular • Vascular Neurology

Clinical outcomes and missed benefits related to clopidogrel overuse in acute coronary syndrome. (PubMed, J Thromb Thrombolysis) - No abstract available

Clinical data • Journal • Acute Coronary Syndrome • Cardiovascular

10-year Follow-up Of Clopidogrel Vs Aspirin Monotherapy In Stable Coronary Artery Disease After Percutaneous Coronary Intervention With Drug-eluting Stent (ACC 2026) - "Abstract is embargoed at this time."

Late-breaking abstract • Monotherapy • Cardiovascular • Coronary Artery Disease

CONCOMITANT STROKE AND ST-ELEVATION MYOCARDIAL INFARCTION IN A PATIENT WITH NEW-ONSET ATRIAL FIBRILLATION (ACC 2026) - "She underwent defibrillation and was started on IV amiodarone and magnesium...New-onset paroxysmal atrial fibrillation prompted initiation of apixaban; aspirin and ticagrelor were switched to clopidogrel... Concurrent stroke and MI with new-onset atrial fibrillation creates competing risks where treatment for one may compromise the other. Risk-benefit discussion and consideration of mortality risk can help guide management."

Clinical • Atherosclerosis • Atrial Fibrillation • Cardiovascular • Myocardial Infarction • Ventricular Tachycardia

PERICARDIAL PRIMARY EFFUSION LYMPHOMA PRESENTING AS ACUTE CORONARY SYNDROME WITH IMMEDIATE STENT THROMBOSIS AND MALIGNANT VENTRICULAR TACHYCARDIA (ACC 2026) - "He was loaded with aspirin and underwent emergent angiography revealing 99% proximal right coronary artery occlusion...Right femoral access was re-established, and he subsequently developed sustained ventricular tachycardia (VT) requiring defibrillation and amiodarone...He received a 2-hour cangrelor infusion, followed by clopidogrel 600mg, and intravenous heparin... Pericardial lymphoma can rarely manifest as ACS with immediate stent thrombosis and ischemia-driven VT. Recognizing malignancy-related hypercoagulability is critical as management may require intensified antithrombotic therapy beyond standard PCI protocols."

Acute Coronary Syndrome • Cardiovascular • Hematological Malignancies • Lymphoma • Monoclonal Gammopathy • Pulmonary Embolism • Respiratory Diseases • Thrombosis • Ventricular Tachycardia

WHEN THE HEART THROWS STONES: EMBOLIC CVA FROM CASEOUS MAC (ACC 2026) - "Medical management with clopidogrel and apixaban was started due to paucity of data regarding optimal treatment and low bleeding risk. CCMA, while rare, is an important consideration in embolic CVAs. Management remains individualized, requiring a balance between surgical risk and the uncertainty of medical therapy."

Cardiovascular • CNS Disorders • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

TRIPLE ANTITHROMBOTIC THERAPY WITH TICAGRELOR VERSUS CLOPIDOGREL IN PATIENTS WITH ATRIAL FIBRILLATION UNDERGOING PCI FOR ACUTE MYOCARDIAL INFARCTION (ACC 2026) - "Background: Triple antithrombotic therapy (TAT), comprising a DOAC, aspirin, and a P2Y12 inhibitor, is recommended for patients with atrial fibrillation (AF) undergoing PCI for acute myocardial infarction (AMI) - for 1 week in low-risk and up to 1 month in high-risk patients. In our real-world analysis, ticagrelor had comparable outcomes to clopidogrel when used as part of TAT, after PCI for AMI in AF/ flutter. Our findings suggest that ticagrelor may be a reasonable alternative, particularly in patients with clopidogrel resistance, warranting further prospective studies."

Clinical • Atrial Fibrillation • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Myocardial Infarction

TRENDS AND INSTITUTIONAL VARIATION IN HIGH-POTENCY P2Y12 INHIBITORS PRESCRIPTION AMONG PATIENTS WITH CHRONIC CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION - AN ANALYSIS FROM THE NCDR CATH PCI REGISTRY (ACC 2026) - "Background: This analysis examines prescription patterns of high-potency P2Y12 inhibitors (ticagrelor or prasugrel) versus clopidogrel among patients with chronic coronary syndrome (CCS) undergoing percutaneous coronary intervention (PCI) in the U.S. This is an observational analysis using the NCDR Cath-PCI registry including patients with CCS undergoing PCI from 2018 to 2024. About one-third of patients with CCS undergoing PCI received high-potency P2Y12 inhibitors at discharge, with wide variability across US institutions. This pattern was influenced by certain patient and procedural factors."

Clinical

THE QUIET TIME BOMB: KAWASAKI DISEASE AND ITS ROLE IN ACUTE CORONARY SYNDROME (ACC 2026) - "The patient was managed medically with tirofiban transitioned to cangrelor, then discharged on dual therapy with clopidogrel and warfarin (INR goal 2-3). Kawasaki disease related coronary aneurysms present unique challenges for revascularization due to ectasia, calcification, thrombus, and competitive flow. In such cases, multidisciplinary evaluation and tailored medical therapy remain central to management."

Acute Coronary Syndrome • Cardiovascular • Myocardial Infarction • Thrombosis • Vasculitis